Reuters

Sanofi sues Eli Lilly over insulin rival to Lantus

(Reuters) - Sanofi SA, whose top-selling Lantus helps diabetics control blood sugar levels, has filed a lawsuit accusing Eli Lilly and Co of infringing seven patents related to insulin and devices ...
Reuters

Sanofi's Lantus drug no cause for concern -EU agency

LONDON, July 23 (Reuters) - The European Union's drug watchdog cast further doubt on recent studies suggesting a possible cancer risk with Sanofi-Aventis's widely-used Lantus diabetes drug. The ...
Nasdaq

Sandoz Secures European Commission Approval For Ondibta, A Biosimilar To Lantus, For Diabetes

(RTTNews) - Sandoz Group AG (SDZ.SW) announced that the European Commission has approved Ondibta (insulin glargine), a biosimilar to Sanofi's Lantus SoloStar, for the treatment of diabetes mellitus ...
Seeking Alpha

Press Release: Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all patients with commercial insurance

Sanofi cuts U.S. list price of Lantus ®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all patients with commercial insurance Paris, March 16, 2023. Sanofi ...